2013-09-19 18:11:02 -
* Significant progress made in the DEINOL programme with the launch of a
series of trials in preindustrial fermenters (300L) in preparation and
increased testing on commercial substrates.
* Acceleration of green chemistry programmes with increased staffing and the
prospect of significant partnerships in the near term.
* Half-year net loss reduced by 8% (loss of 1.3 million Euros vs. a loss 1.4
million Euros in H1 2012).
* Sufficient cash resources to cover the Company's needs until Q3 2014, a
significant improvement on guidance made earlier this year.
Paris, 19 September 2013 - DEINOVE (Alternext Paris: ALDEI), a cleantech company
that designs, develops
and markets the next generation of industrial processes
based on the Deinococcus bacteria, today announced its interim results for 2013.
The net result for the first half of 2013 is a loss of 1.3 million Euros. In the
absence of significant operating revenues, this result includes 2.6 million
Euros in operating expenses, a positive financial result of 55 thousand Euros,
non-recurring income of 68 thousand Euros, and an R&D tax credit of 1.2 million
Euros. The increase in operating expenses (up 456 thousand Euros vs. H1 2012) is
mainly due to the consolidation of R&D efforts regarding the DEINOL and
DEINOCHEM programmes (including 4 new full time employees or FTEs).
The net financial position is +4.1 million Euros, compared to +6.5 million Euros
at the end of 2012. This figure does not include the receipt of 0.9 million
Euros relating to the 2012 R&D tax credit, paid on 4 July 2013 (see press
release dated 15 July 2013). DEINOVE also filed an adjustment request of 658
thousand Euros with the relevant tax office relating to R&D tax credits due for
2010 and 2011. This amount is accrued in full in the accounts at 30 June 2013.
Excluding new financing and revenues from new partnerships, the Company believes
that it currently has the means to finance programmes underway until at least
the third quarter of 2014, which represents a significant improvement on
guidance made earlier this year.
R&D activities focused on strengthening the metabolic engineering platform
dedicated to the Deinococcus bacteria, of which the Company is the only one in
the world to make use, as well as continuing its DEINOL (aiming to develop a
breakthrough bioprocess for the production of 2(nd) generation cellulosic
ethanol) and DEINOCHEM (for the production of bio-based chemical compounds)
Emmanuel PETIOT, CEO of DEINOVE stated: "DEINOVE is currently on the verge of a
major technological breakthrough in the field of metabolic engineering. Our
exclusive bacterial fermentation process - which is now robust and compatible
with an industrial environment - should pave the way for new industrial
production systems that will contribute to an oil-free economy. By improving
significantly the performance of our bacteria, we are entering into relationship
with many industrial players worldwide.
Today our cash resources are sufficient to cover our financing needs until the
3(rd) quarter of 2014, which reflects excellent cost and cash management at a
time when we have significantly increased our research efforts."
Emmanuel Petiot Julien Coste
CEO Director of Finance & Administration
Tel.: + 33 1 42 03 27 37
Tel.: + 33 1 42 03 27 37
Mob.: +33 6 26 94 18 53
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Deinove via Thomson Reuters ONE